Key Takeaways HIMS surged 90.4% in three months, outpacing peers and driven by gains in online revenue and subscribers. Expansion into Canada and the ZAVA acquisition mark major international growth milestones for HIMS. HIMS projects up to 74% Q2 revenue growth and 63% full-year growth, fueled by demand for GLP-1 therapies.Hims & Hers Health, Inc.’s (HIMS) investors have been experiencing some short-term gains from the stock lately despite its bumpy ride over recent months. The San Francisco, CA-based hea ...

NEW YORK, July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=156860&from=4CLASS PERIOD: April 29, ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a national ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Hims common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

PHILADELPHIA, July 16, 2025 /PRNewswire/ -- Berger Montague announces a securities fraud investigation into Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) concerning potential violations of the Securities Exchange Act of 1934. The inquiry focuses on whether investors were misled about the Company's regulatory compliance and business operations.Following Novo Nordisk's termination of its collaboration with Hims & Hers on June 23, 2025, the Company's stock dropped more than 34%. A class ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, to seek lead plaintiff status [1]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding the safety of its products [2]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices that jeopardized patient safety, leading to a stock price decline of over 34% [3]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Hims & Hers securities during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [4]. Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=156722&from=3 CLASS PERIOD: A ...

智通财经APP获悉，专注于通过线上平台提供远程医疗服务和个性化健康产品的Hims & Hers Health (HIMS.US)与全球减肥药领军者诺和诺德(NVO.US)之间短暂合作关系的突然终止，导致针对这家远程 医疗公司的投资者诉讼麻烦不断增加。 在本周，一群股东在旧金山联邦法院对 Hims & Hers提起诉讼。据媒体报道，这起于周一递交的所谓派 生诉讼称，Hims & Hers 董事会及其高管就公司的财务状况与业务经营，以及关于未来业绩指引发表了 虚假且具有误导性的信息。 Hims & Hers Health与诺和诺德之间由"闪婚"到"闪离"的戏剧性短期合作，触发了前者股价暴跌、投资 者集体诉讼Hims & Hers Health以及双方隔空"口水战"。 投资者们随后在旧金山联邦法院对Hims & Hers 提起数起证券集体诉讼，指控公司对合作重要性、合规 风险披露不足。 今年6月，丹麦制药巨头诺和诺德终止了一项仅仅签订约两个月的合作协议，此前双方达成合作，让 Hims & Hers的会员们可通过直销平台NovoCare Pharmacy 获得其有着"减肥神药"称号的减重药物 Wegovy。受此影响， ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

Core Insights - The stock of Hims & Hers Health (NYSE: HIMS) was initially discovered when trading around $20, and a 50% return was realized upon selling, although a subsequent bullish run was missed [1]. Company Profile - Hims & Hers Health operates in the healthcare sector, focusing on telehealth services and wellness products, which have gained traction in recent years due to increased consumer demand for accessible healthcare solutions [1]. Analyst Background - The analyst has a strong background in finance and risk analysis, holding an MSc in Applied Risk Management and having worked in various roles across leading firms, indicating a solid foundation for evaluating investment opportunities [1]. Investment Strategy - The approach to investing emphasizes data-driven analysis and long-term value creation, with a focus on risk management and financial modeling, which are critical for assessing the potential of stocks like Hims & Hers Health [1].